The obese older female patient: CV risk and the SCOUT study

International Journal of Obesity

Volumn 31, Issue , 2007, Pages S26-S30

  Coutinho, W F ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cardiovascular risk; Randomized trial; SCOUT; Weight loss; Women

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; SIBUTRAMINE;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STROKE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; UNSTABLE ANGINA PECTORIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; AGED; APPETITE DEPRESSANTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYCLOBUTANES; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 35648956293     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803733     Document Type: Article

References (24)

1. World Health Organization Statistical Information System 2004. www.who.int/whosis/.
2. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27: 994–1005.
3. Bello N, Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 2004; 46: 287–295.
4. Herlitz J, Starke M, Hansson E, Ringvall E, Karlson BW, Waagstein L. Characteristics and outcome among women and men transported by ambulance due to symptoms arousing suspicion of acute coronary syndrome. Med Sci Monit 2002; 8: CR251–CR256.
5. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304.
6. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–322.
7. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sexbased differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999; 341: 217–225.
8. Maynard C, Litwin PE, Martin JS, Weaver WD. Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med 1992; 152: 972–976.
9. Wong Y, Rodwell A, Dawkins S, Livesey SA, Simpson IA. Sex differences in investigation results and treatment in subjects referred for investigation of chest pain. Heart 2001; 85: 149–152.
10. Gregor RD, Bata IR, Eastwood BJ, Garner JB, Guernsey JR, MacKenzie BR et al. Gender differences in the presentation, treatment, and short-term mortality of acute chest pain. Clin Invest Med 1994; 17: 551–562.
11. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001; 322: 832.
12. Fleury J, Keller C, Murdaugh C. Social and contextual etiology of coronary heart disease in women. J Womens Health Gend Based Med 2000; 9: 967–978.
13. Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? BMJ 1994; 309: 563–566.
14. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999; 341: 1359–1367.
15. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii–iv, 1–182.
16. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.
17. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
18. Knoops KT, de Groot LC, Kromhout D, Perrin A, Moreiras-Varela O, Menotti A et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292: 1433–1439.
19. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 1995; 141: 1128–1141.
20. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499–1504.
21. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; 3: CD004094.
22. James WPT. The SCOUT study: risk–benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005; 7 (Suppl 7): L44–L48.
23. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni AP et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007: [e-pub ahead of print, doi: 10.1093/eurheartj/ehm217].
24. Van Gaal L, Caterson I, Coutinho W, Finer N, Maggioni AP, Sharma AM et al. Endocrinol Metabol Nutr 2006; 15: 270. Abstract CO 30. www.who.int/whosis